These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16034040)

  • 1. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.
    Pawlik TM; Ross MI; Thompson JF; Eggermont AM; Gershenwald JE
    J Clin Oncol; 2005 Jul; 23(21):4588-90. PubMed ID: 16034040
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sentinel lymph node biopsy and incidence of recurrence].
    Hautarzt; 2006 Mar; 57(3):182. PubMed ID: 17429861
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.
    Molenkamp BG; Statius Muller MG; Vuylsteke RJ; van der Sijp JR; Meijier S; van Leeuwen PA
    Eur J Surg Oncol; 2005 Mar; 31(2):211-2. PubMed ID: 15698742
    [No Abstract]   [Full Text] [Related]  

  • 4. The chances of a patient with melanoma developing in transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB).
    Russell-Jones R; Powell AM; Acland K; Calonje E; O'Doherty M; Healy C
    Eur J Surg Oncol; 2005 Mar; 31(2):210-1. PubMed ID: 15698741
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sentinel node diagnosis in malignant melanoma. Reflections on relapse after histologically negative sentinel node].
    Abrahamsen HN; Larsen J; Hamilton-Dutoit SJ; Rasmussen K; Steiniche T
    Ugeskr Laeger; 2003 Sep; 165(39):3735-6. PubMed ID: 14558388
    [No Abstract]   [Full Text] [Related]  

  • 6. [Risk factors for in-transit metastasis in patients with cutaneous melanoma].
    Clemente-Ruiz de Almiron A; Serrano-Ortega S
    Actas Dermosifiliogr; 2012 Apr; 103(3):207-13. PubMed ID: 21899829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of sentinel lymph nodes in melanoma: technique versus rationale.
    Rosai J; Coit DG; Spanknebel K; Klimstra DS
    Am J Surg Pathol; 2006 Mar; 30(3):417-8; author reply 420-1. PubMed ID: 16538066
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prognosis after sentinel node biopsy in malignant melanoma].
    Lock-Andersen J; Horn J; Sjøstrand H
    Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark.
    Pawlik TM; Ross MI; Shaw HM; Thompson JF; Gershenwald JE
    Eur J Surg Oncol; 2005 Apr; 31(3):323-4. PubMed ID: 15780572
    [No Abstract]   [Full Text] [Related]  

  • 10. The evolution of the management of regional lymph nodes in melanoma.
    Landry CS; McMasters KM; Scoggins CR
    J Surg Oncol; 2007 Sep; 96(4):316-21. PubMed ID: 17879333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with local and in-transit recurrence of cutaneous melanoma.
    Stucky CC; Gray RJ; Dueck AC; Wasif N; Laman SD; Sekulic A; Pockaj BA
    Am J Surg; 2010 Dec; 200(6):770-4; discussion 774-5. PubMed ID: 21146019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsies for cutaneous melanoma.
    Victoria Giblin A; Meirion Thomas J
    Am J Surg Pathol; 2006 Mar; 30(3):418-9; author reply 420-1. PubMed ID: 16538067
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
    Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
    Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of variations between surgeons regarding inguinal lymph node clearance in melanoma].
    Danino MA; Trost O; Malka G; Garrido I; Jebrane A; Dalac S
    Ann Dermatol Venereol; 2008 Feb; 135(2):142-4. PubMed ID: 18342100
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of the surgeon in the management of melanoma.
    Sabel MS; Arora A
    Minerva Chir; 2006 Apr; 61(2):141-54. PubMed ID: 16871145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
    Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
    Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of total number of sentinel lymph nodes in patients with stage N0 cutaneous melanoma.
    Stewart LE; Tyler DS; Vollmer RT
    Am J Clin Pathol; 2005 Jul; 124(1):77-82. PubMed ID: 16086501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
    Zogakis TG; Essner R; Wang HJ; Foshag LJ; Morton DL
    Ann Surg Oncol; 2007 May; 14(5):1604-11. PubMed ID: 17333418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-transit recurrence after sentinel lymph node biopsy in melanoma: primum non nocere.
    Coit DG
    Ann Surg Oncol; 2005 Aug; 12(8):575-8. PubMed ID: 15965729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.